Wed, May 14, 10:01 AM (35 days ago)
### Summary of Applied Therapeutics, Inc. (APLT) Q1 2025 Financial Performance **Financial Health and Performance Metrics:** - **Revenue:** $0 (Q1 2024: $190,000) - **Net Loss:** $21.8 million (Q1 2024: $83.9 million) - **Cash and Cash Equivalents:** $50.8 million (Q1 2024: $79.4 million) - **Total Assets:** $56.9 million (Q1 2024: $86.7 million) - **Total Liabilities:** $20.2 million (Q1 2024: $29.7 million) - **Stockholders' Equity:** $36.7 million (Q1 2024: $57.0 million) **Profit Margins:** - **Gross Margin:** Not applicable (no revenue) - **Operating Margin:** Not applicable (no revenue) - **Net Margin:** Not applicable (no revenue) **Cash Flow:** - **Operating Activities:** -$28.6 million (Q1 2024: -$18.9 million) - **Investing Activities:** $0 (Q1 2024: $0) - **Financing Activities:** $0 (Q1 2024: $115.5 million) **Earnings Changes:** - **Net Loss per Share:** -$0.15 (Q1 2024: -$0.67) **Quarterly Performance Discussion:** - **Revenue:** No revenue generated in Q1 2025, a decrease from $190,000 in Q1 2024. - **Operating Expenses:** Total costs and expenses were $25.5 million, down from $21.3 million in Q1 2024. - **Research and Development:** Expenses decreased to $7.8 million from $12.2 million. - **General and Administrative:** Expenses increased to $17.7 million from $9.1 million. - **Other Income (Expense):** Net other income was $3.7 million, a significant improvement from -$62.8 million in Q1 2024. **Trends and Uncertainties:** - **Liquidity:** The company has $50.8 million in cash and cash equivalents but faces substantial doubt regarding its ability to continue as a going concern for the next 12 months. - **Funding Requirements:** The company will need substantial additional funding to support ongoing operations and planned research and clinical development activities. - **Operational Impact:** The company is dependent on debt and equity financing to fund its operations due to the lack of product revenue. **Future Operations Impact:** - **Clinical Trials:** The company is actively working on several clinical trials, including those for AT-007 (govorestat) and AT-001 (caficrestat). - **Regulatory Approvals:** The company is seeking regulatory approvals for its product candidates and faces uncertainties related to the FDA's Complete Response Letter and Warning Letter. - **Commercialization:** The company is preparing for potential commercialization of its product candidates, including AT-007 for Classic Galactosemia and SORD Deficiency. **Note:** The company's financial health is precarious, with significant operating losses and dependence on external financing. The success of its clinical trials and regulatory approvals will be critical for its future operations and financial stability.